- | COUR Pharmaceuticals
Tolerogenic Therapies Retrain the Immune System
COUR Pharmaceuticals’ emerging platform reprograms the immune system to address the root causes of autoimmune diseases
- | Tessera Therapeutics
Tessera Therapeutics Advances In Vivo Gene Therapy For SCD
Last year, Tessera Therapeutics’ CEO, Dr. Michael Severino, was my guest on Cell & Gene: The Podcast to discuss Gene Writing, the biotech’s genome
- | COUR Pharmaceuticals
Chicago Area’s Life Sciences Scene Continues Making an Impression
Chicago Biomedical Consortium and COUR Pharmaceuticals executives share what makes the area a hot spot.
- | LB Pharmaceuticals
With schizophrenia trial success, LB Pharmaceuticals thinks about Phase 3 and next funding
A private startup looking to bring an old schizophrenia drug class to the US has released new Phase 2 data and aims to start a …
- | LB Pharmaceuticals
LB Pharma’s twist on old Sanofi drug passes schizophrenia test, teeing up phase 3 push
LB Pharmaceuticals has shared top-line data from a phase 2 schizophrenia trial, touting results that offer early support for its vision and putting it on track to start a pivotal study around the end of the year.
- | MindMed
First Patient Dosed in Phase 3 Study of Psychedelic MM120 in Generalized Anxiety Disorder
MindMed announced the first patient had been dosed in the first-ever phase 3 trial of lysergic acid-diethylamide (LSD) for generalized anxiety disorder (GAD). MindMed is currently the furthest along in clinical trials exploring LSD as a treatment in multiple psychiatric indications, including major depressive disorder.
- | COUR Pharmaceuticals
Internalizing Nanoparticle Therapeutic Development
COUR Pharmaceuticals has been, as its newly-appointed President & CEO Dannielle Appelhans puts it, flying under the radar for a long time. COUR made a splash back in 2015, when it formed up around a biodegradable nanoparticle encapsulating gliadin proteins that proved to reverse the effects of gluten in animal models.
- | Interius Biotherapeutics
Philadelphia based Interius BioTherapeutics recently dosed the first patient for its in vivo CAR therapy that edits T and NK cells in the body so they target CD20 positive cells in B-cell malignancies
V.P. of R&D Tim Culp describes the rationale for in vivo CAR programs, what the company will be watching for from a safety standpoint, the development path ahead, and competition.
